Is anti-hormonal treatment in DCIS of the breast a need?

Ductal carcinomas in situ (DCIS) represent one fifth of all detected breast cancers. The detection of DCIS can be regarded as collateral damage of breast cancer screening. The treatment of DCIS is based on surgery with or without radiotherapy. Women treated for DCIS have a 10 years survival of 98 %....

Descripción completa

Detalles Bibliográficos
Autor principal: Tjalma, WAA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Universa Press 2016
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5172575/
https://www.ncbi.nlm.nih.gov/pubmed/28003873
_version_ 1782484153020710912
author Tjalma, WAA
author_facet Tjalma, WAA
author_sort Tjalma, WAA
collection PubMed
description Ductal carcinomas in situ (DCIS) represent one fifth of all detected breast cancers. The detection of DCIS can be regarded as collateral damage of breast cancer screening. The treatment of DCIS is based on surgery with or without radiotherapy. Women treated for DCIS have a 10 years survival of 98 %. Could there be a role for systemic therapy in case of a DCIS? Recent published studies suggest there is. However, anti-hormonal therapy (tamoxifen, anastrozole) in DCIS causes an increased morbidity without a reduced mortality. There is an urgent need for evidence-based guidelines in the management of DCIS in order to make appropriate shared decisions.
format Online
Article
Text
id pubmed-5172575
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Universa Press
record_format MEDLINE/PubMed
spelling pubmed-51725752016-12-21 Is anti-hormonal treatment in DCIS of the breast a need? Tjalma, WAA Facts Views Vis Obgyn Short Communication Ductal carcinomas in situ (DCIS) represent one fifth of all detected breast cancers. The detection of DCIS can be regarded as collateral damage of breast cancer screening. The treatment of DCIS is based on surgery with or without radiotherapy. Women treated for DCIS have a 10 years survival of 98 %. Could there be a role for systemic therapy in case of a DCIS? Recent published studies suggest there is. However, anti-hormonal therapy (tamoxifen, anastrozole) in DCIS causes an increased morbidity without a reduced mortality. There is an urgent need for evidence-based guidelines in the management of DCIS in order to make appropriate shared decisions. Universa Press 2016-09 2016-12-05 /pmc/articles/PMC5172575/ /pubmed/28003873 Text en Copyright © 2016 Facts, Views & Vision http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Tjalma, WAA
Is anti-hormonal treatment in DCIS of the breast a need?
title Is anti-hormonal treatment in DCIS of the breast a need?
title_full Is anti-hormonal treatment in DCIS of the breast a need?
title_fullStr Is anti-hormonal treatment in DCIS of the breast a need?
title_full_unstemmed Is anti-hormonal treatment in DCIS of the breast a need?
title_short Is anti-hormonal treatment in DCIS of the breast a need?
title_sort is anti-hormonal treatment in dcis of the breast a need?
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5172575/
https://www.ncbi.nlm.nih.gov/pubmed/28003873
work_keys_str_mv AT tjalmawaa isantihormonaltreatmentindcisofthebreastaneed

Ejemplares similares